ENZYMATIC CYCLIZATION OF TERPENOID NATURAL PRODUCTS
Project Number2R01GM031354-10
Contact PI/Project LeaderCROTEAU, RODNEY B
Awardee OrganizationWASHINGTON STATE UNIVERSITY
Description
Abstract Text
Monoterpene cyclases (synthases) provide the focus for study of allylic
pyrophosphate cyclization, a reaction type of major importance in C-C bond
formation in the biosynthesis of numerous terpenoid natural products of
pharmacological significance. A general stereochemical model has been
proposed for the coupled isomerization-cyclization of the universal
isoprenoid precursor, geranyl pyrophosphate, and key mechanistic elements
of the scheme were confirmed through studies on the origin of the seven
major monoterpene skeletal types. A selected set of cyclases [(+)- and (-
)limonene synthase, (+)- and (-)-pinene synthase, and (+)- and (-)-bornyl
pyrophosphate synthase] that differ significantly in mechanistic detail
will be employed to examine active site structure-function relationships
that underlie reaction variants. As the prototype, (-)-4S-limonene
synthase was purified from isolated oil glands of Mentha and, from amino
acid sequence information, degenerate oligonucleotide probes were prepared
for screening an oil gland cDNA library, from which three full-length
clones were isolated. These cDNA isolates were sequenced and verified by
functional expression in Escherichia coil. Based on positive RNA blot
hybridization and direct sequence comparison at the protein level, the (-
)-limonene cyclase cDNA provides a powerful heterologous probe for
isolating the cDNAs encoding the other monoterpene cyclases from the
corresponding gland libraries of Salvia, Tanacetum and Citrus species.
Where heterologous cDNA probing is not possible, an alternate strategy for
purifying the target cyclase, and obtaining the gene, has been devised
based on specific labeling of the protein with a mechanism-based
inhibitor. A bacterial overexpression system based on the PET vector will
be devised that permits rapid purification of the recombinant cyclases.
The roles of active site cysteine and histidine residues in binding and
catalysis were suggested by inhibition studies and by determining the
protective influence of substrate and analogues representing different
substrate binding domains. A photolabile substrate analogue was utilized
for photoaffinity labeling of the presumptive hydrophobic pocket of the
cyclases, and the mechanism-based inhibitor was used for labeling putative
active site bases involved in terminating deprotonations. With these
probes, labeled active site peptides will be generated for sequencing and
location on the deduced primary structures. This information, plus that
gained by primary sequence comparisons, will be used to target active site
residues for mutagenesis. The mutant cyclases will be characterized with
respect to kinetic behavior and product mixture, and a variety of
biochemical techniques employed to deduce which step(s) of the complex
reaction cascade have been altered. A series of substrate analogues will
be used to examine the cryptic isomerization step of the reaction and to
explore the catalytic repertoire of the cloned cyclases. The studies
outlined should provide new information on the nature of these novel
catalysts, particularly the relationship of enzyme structure to reaction
mechanism, and allow a clearer understanding of this important aspect of
prenyl pyrophosphate metabolism.
No Sub Projects information available for 2R01GM031354-10
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01GM031354-10
Patents
No Patents information available for 2R01GM031354-10
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01GM031354-10
Clinical Studies
No Clinical Studies information available for 2R01GM031354-10
News and More
Related News Releases
No news release information available for 2R01GM031354-10
History
No Historical information available for 2R01GM031354-10
Similar Projects
No Similar Projects information available for 2R01GM031354-10